Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration

被引：0
|
作者：
Pickar-Oliver, Adrian [1 ]
Nelson, Christopher [1 ]
Bohning, Joel [1 ]
Gemberling, Matthew [1 ]
Bulaklak, Karen [1 ]
Gersbach, Charles A. [1 ]
机构：
[1] Duke Univ, Biomed Engn, Durham, NC USA
来源：
MOLECULAR THERAPY | 2019年 / 27卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
380
引用
收藏
页码：180 / 181
页数：2
相关论文
共 50 条
  • [21] CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
    Cedric Happi Mbakam
    Gabriel Lamothe
    Guillaume Tremblay
    Jacques P. Tremblay
    Neurotherapeutics, 2022, 19 : 931 - 941
  • [22] CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy
    Heather Wood
    Nature Reviews Neurology, 2015, 11 (4) : 184 - 184
  • [23] A Novel Utrophin-Based Genome Engineering Strategy for Duchenne Muscular Dystrophy Utilizing Recombinases and CRISPR/Cas9
    Geisinger, Jonathan M.
    Bjornson, Christopher B.
    Neal, Tawny L.
    Calos, Michele P.
    MOLECULAR THERAPY, 2014, 22 : S125 - S125
  • [24] Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients
    Solberg, Marthe Helene
    Shariatzadeh, Maryam
    Wilson, Samantha L.
    Engineering Biology, 2020, 4 (03) : 37 - 42
  • [25] CRISPR/Cas9 mediated gene editing of Duchenne muscular dystrophy with a single gene deleted adenoviral vector
    Ehrke-Schulz, E.
    Mouly, V.
    Ehrhardt, A.
    HUMAN GENE THERAPY, 2019, 30 (11) : A161 - A161
  • [26] Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
    Mollanoori, Hasan
    Rahmati, Yazdan
    Hassani, Bita
    Mehr, Meysam Havasi
    Teimourian, Shahram
    GENES & DISEASES, 2021, 8 (02) : 146 - 156
  • [27] Spell-checking nature: interrogating the versatility of the CRISPR/Cas9 system for the treatment of Duchenne Muscular Dystrophy
    Wojtal, D.
    Kemaladewi, D. U.
    Malam, Z.
    Abdullah, S.
    Wong, T. W. Y.
    Hyatt, E.
    Pereira, S.
    Stavropoulos, J.
    Mouly, V.
    Mamchaoui, K.
    Muntoni, F.
    Voit, T.
    Gonorazky, H.
    Dowling, J. J.
    Mendoza-Londono, R.
    Ivakine, E.
    Cohn, R. D.
    HUMAN GENE THERAPY, 2015, 26 (10) : A15 - A15
  • [28] Characterization of CRISPR/Cas9-induced genomic alterations and AAV targeted integration in human HSPC
    Tachtsidi, A.
    Corre, G.
    Amendola, M.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A143 - A144
  • [29] Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening 
    Patricia Soblechero-Martín
    Edurne Albiasu-Arteta
    Aina Anton-Martinez
    Laura de la Puente-Ovejero
    Iker Garcia-Jimenez
    Gabriela González-Iglesias
    Irene Larrañaga-Aiestaran
    Andrea López-Martínez
    Javier Poyatos-García
    Estíbaliz Ruiz-Del-Yerro
    Federico Gonzalez
    Virginia Arechavala-Gomeza
    Scientific Reports, 11
  • [30] Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening
    Soblechero-Martin, Patricia
    Albiasu-Arteta, Edurne
    Anton-Martinez, Aina
    de la Puente-ovejero, Laura
    Garcia-Jimenez, Iker
    Gonzalez-Iglesias, Gabriela
    Larranaga-Aiestaran, Irene
    Lopez-Martinez, Andrea
    Poyatos-Garcia, Javier
    Ruiz-Del-Yerro, Estibaliz
    Gonzalez, Federico
    Arechavala-Gomeza, Virginia
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345